Soligenix, Inc. financial data

Symbol
SNGX on Nasdaq
Industry
Pharmaceutical Preparations
Location
29 Emmons Drive, Suite B 10, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
DOR BIOPHARMA INC (to 9/29/2009), ENDOREX CORP (to 10/24/2001), IMMUNOTHERAPEUTICS INC (to 4/30/1996)
Latest financial report
10-Q - Q3 2024 - Nov 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 154 % +22.9%
Debt-to-equity 201 % -81.9%
Return On Equity -224 % +71.2%
Return On Assets -74.3 % -16.3%
Operating Margin -1.57K % -50.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.51M shares -75.8%
Common Stock, Shares, Outstanding 2.3M shares -77.9%
Entity Public Float 6.85M USD -73.4%
Common Stock, Value, Issued 2.3K USD -77.9%
Weighted Average Number of Shares Outstanding, Basic 2.2M shares +240%
Weighted Average Number of Shares Outstanding, Diluted 2.2M shares +240%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 495K USD -50.4%
Cost of Revenue 451K USD -33.2%
Research and Development Expense 3.34M USD -31.7%
General and Administrative Expense 4.55M USD +0.1%
Operating Income (Loss) -7.86M USD +13.9%
Nonoperating Income (Expense) 159K USD +25.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.71M USD +16.6%
Income Tax Expense (Benefit) -1.16M USD
Net Income (Loss) Attributable to Parent -7.1M USD +12.1%
Earnings Per Share, Basic 3.42 USD/shares +69.5%
Earnings Per Share, Diluted 3.42 USD/shares +69.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.9M USD -25.1%
Assets, Current 10.3M USD -6.06%
Property, Plant and Equipment, Net 7.16K USD -47%
Operating Lease, Right-of-Use Asset 140K USD -45.8%
Other Assets, Noncurrent 3.88K USD -80%
Assets 10.5M USD -7.31%
Accounts Payable, Current 891K USD -39%
Employee-related Liabilities, Current 84.4K USD +51.9%
Accrued Liabilities, Current 1.36M USD -42.9%
Contract with Customer, Liability, Current 100K USD
Liabilities, Current 4.53M USD -18%
Contract with Customer, Liability, Noncurrent 100K USD
Operating Lease, Liability, Noncurrent 11.5K USD -92%
Liabilities 4.54M USD -35.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 37.5K USD +54.1%
Retained Earnings (Accumulated Deficit) -231M USD -3.17%
Stockholders' Equity Attributable to Parent 5.94M USD +40.6%
Liabilities and Equity 10.5M USD -7.31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.34M USD +38%
Net Cash Provided by (Used in) Financing Activities -8.99K USD +99%
Net Cash Provided by (Used in) Investing Activities -9.82K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 2.3M shares -77.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.35M USD +56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.84M USD -4.45%
Interest Paid, Excluding Capitalized Interest, Operating Activities 64K USD -70%
Deferred Tax Assets, Valuation Allowance 40.4M USD +1.24%
Cash and Cash Equivalents, Period Increase (Decrease) 3.17M USD
Deferred Tax Assets, Gross 40.5M USD +1.16%
Operating Lease, Liability 368K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.09M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid 234K USD -39.6%
Operating Lease, Liability, Current 132K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 116K USD -15.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 137K USD +2.32%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19.5K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 116K USD
Deferred Tax Assets, Operating Loss Carryforwards 27.5M USD +0.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 350K shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 26.3K USD -15.1%
Additional Paid in Capital 237M USD +3.86%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 33.5K USD -37.5%
Deferred Tax Assets, Net of Valuation Allowance 65K USD -32.3%